<DOC>
	<DOCNO>NCT01381510</DOCNO>
	<brief_summary>Adherence length therapy 5-alpha reductase inhibitor ( 5ARI ) treatment may associate improved clinical outcome enlarge prostate ( EP ) well low health care cost . The objective retrospective database analysis quantify relationship adherence length therapy 5ARI likelihood acute urinary retention ( AUR ) prostate surgery ( emergency non-emergency ) patient benign prostatic hyperplasia ( BPH ) . The study also measure economic impact associate medical encounter . The MarketScan database contain data people commercial health insurance Medicare include medical pharmacy data source directly health plan employer . Approximately 18 million covered life utilized study time period January 1 , 2003 September 30 , 2009 . This study retrospective cohort analysis medical claim data .</brief_summary>
	<brief_title>Establishing Benefits Adherence Enlarged Prostate Treatment : A Validation Study Linking Adherence Outcomes Using Market Scan Database</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>5-alpha Reductase Inhibitors</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Male Aged 50 year old A diagnostic claim benign prostatic hyperplasia ( International Classification Diseases , Ninth Revision , Clinical Modification [ ICD9CM ] cod 222.2x 600.xx ) A prescription claim 5alpha reductase inhibitor ( 5ARI ) least 60 day observation period Continuous health plan eligibilitiy 6 month prior least 150 day initial 5ARI prescription A diagnosis prostate cancer ( ICD9CM cod 185.xx , 198.82 , 233.4 , 236.5 , 239.5 , V10.46 ) A diagnosis bladder cancer ( ICD9CM cod 188.xx , 198.1 , 223.3 , 233.7 , 239.4 , V10.51 ) , A procedure code prostaterelated surgery prior index date 150 day index date A diagnosis code acute urinary retention ( AUR ) prior index date 150 day index date</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Benign prostatic hyperplasia</keyword>
	<keyword>Adherence</keyword>
	<keyword>Acute urinary retention</keyword>
	<keyword>Enlarged prostate</keyword>
	<keyword>5-alpha reductase inhibitor</keyword>
	<keyword>Surgery</keyword>
	<keyword>Cost cost analysis</keyword>
</DOC>